Marrow fat and bone: New insights from mice and humans

Clinical Reviews in Bone and Mineral Metabolism

Volumn 7, Issue 3, 2009, Pages 216-223

  Kawai, Masanobu ^a   Rosen, Clifford J ^a  

^a Maine Medical Center Research Institute   (United States)

Author keywords

Marrow fat; PPAR ; Skeletal acquisition

Indexed keywords

EID: 84905098736     PISSN: 15348644     EISSN: 15590119     Source Type: Journal    
DOI: 10.1007/s12018-009-9050-x     Document Type: Article

References (96)

1. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol. 2000;16:145-71. (Pubitemid 32037503)
2. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006;7:885-96. (Pubitemid 44871415)
3. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-34.
4. Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, et al. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. J Pharmacol Exp Ther. 2006;318:863-71. (Pubitemid 44061262)
5. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci. 1994;91:7355-9. (Pubitemid 24226862)
6. Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev. 2004;25:899-918. (Pubitemid 39657772)
7. Cock T-A, Houten SM, Auwerx J. Peroxisome proliferator-activated receptor gamma: too much of a good thing causes harm. EMBO Rep. 2004;5:142-7. (Pubitemid 38401192)
8. Hagman J, Belanger C, Travis A, Turck CW, Grosschedl R. Cloning and functional characterization of early B-cell factor, a regulator of lymphocyte-specific gene expression. Genes Dev. 1993;7:760-73. (Pubitemid 23163581)
9. Jimenez MA, Akerblad P, Sigvardsson M, Rosen ED. Critical role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade. Mol Cell Biol. 2007;27:743-57. (Pubitemid 46080139)
10. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 2007;13:1496-503.
11. Elbrecht A, Chen Y, Cullinan C, Hayes N, Leibowitz M, Moller D, et al. Molecular cloning, expression and characterization of human peroxisome activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun. 1996;224:431-7. (Pubitemid 26268204)
12. Gimble JM, Robinson CE, Wu X, Kelly K, Rodriguez BR, Kliewer SA, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996;50:1087-94. (Pubitemid 26384846)
13. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem. 1999;74:357-71. (Pubitemid 29344887)
14. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung U-I, Kubota N, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113:846-55. (Pubitemid 38544143)
15. Horowitz M, Bothwell A, Hesslein D, Pflugh D, Schatz D. B cells and osteoblast and osteoclast development. Immunol Rev. 2005;208:141-53. (Pubitemid 41746390)
16. Tornvig L, Mosekilde L, Justesen J, Falk E, Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int. 2001;69:46-50. (Pubitemid 32702265)
17. Aleo MD, Lundeen GR, Blackwell DK, Smith WM, Coleman GL, Stadnicki SW, et al. Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-{gamma} agonist. J Pharmacol Exp Ther. 2003;305:1173-82. (Pubitemid 36617996)
18. Li M, Pan LC, Simmons HA, Li Y, Healy DR, Robinson BS, et al. Surface-specific effects of a PPAR agonist, darglitazone, on bone in mice. Bone. 2006;39:796-806. (Pubitemid 44311719)
19. Lazarenko O, Rzonca S, Suva L, Lecka-Czernik B. Netoglitazone is a PPAR gamma ligand with selective effects on bone and fat. Bone. 2006;38:74-84. (Pubitemid 43006077)
20. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, et al. Activation of peroxisome proliferator-activated receptor γ (PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology. 2007; 148:903-11. (Pubitemid 46143190)
21. Gimble JM. Marrow stromal adipocytes. In: Beresford J, Owen M, editors. Marrow stromal cell cuture. Cambridge: Cambridge University Press; 1998. p. 67-87.
22. Soroceanu M, Miao D, Bai X, Su H, Goltzman D, Karaplis A. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol. 2004;183:203-16. (Pubitemid 40124657)
23. Ackert-Bicknell CL, Demissie S, Marín de Evsikova C, Hsu YH, DeMambro VE, Karasik D, et al. PPARG by dietary fat interaction influences bone mass in mice and humans. J Bone Miner Res. 2008;23:1398-408.
24. Hamrick M, Ferrari S. Leptin and the sympathetic connection of fat to bone. Osteoporos Int. 2008;19:905-12. (Pubitemid 351758616)
25. Ingalls A, Dickie M, Snell G. Obese, a new mutation in the house mouse. J Heret. 1950;41:317-8.
26. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-32. (Pubitemid 24365442)
27. Charlton HM. Mouse mutants as models in endocrine research. Q J Exp Physiol. 1984;69:655-76. (Pubitemid 15213610)
28. Hamrick MW, Pennington C, Newton D, Xie D, Isales C. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone. 2004;34:376-83. (Pubitemid 38314902)
29. Ducy P, Amling M, Takeda S, Priemel FT, Shen J, Vinson C, et al. Leptin inhibits bone formation through a hypothalimic relay: a central control of bone mass. Cell. 2000;100:197-207. (Pubitemid 30064908)
30. Hess R, Pino AM, Ríos S, Fernández M, Rodríguez JP. High affinity leptin receptors are present in human mesenchymal stem cells (MSCs) derived from control and osteoporotic donors. J Cell Biochem. 2005;94:50-7. (Pubitemid 41420323)
31. Hamrick MW, Della-Fera MA, Choi Y-H, Pennington C, Hartzell D, Baile CA. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res. 2005;20:994-1001. (Pubitemid 40712824)
32. Hamrick M, Della Fera M, Choi Y-H, Hartzell D, Pennington C, Baile C. Injections of leptin into rat ventromedial hypothalamus increase adipocyte apoptosis in peripheral fat and in bone marrow. Cell Tissue Res. 2007;327:133-41. (Pubitemid 44833056)
33. Irwin R, Lin H, Motyl K, McCabe LR. Normal Bone density in the absence of insulin receptor expression in bone. Endocrinology. 2006;147:5760-7. (Pubitemid 44833492)
34. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem. 2007;102:1343-57. (Pubitemid 350223938)
35. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone adiposity and peroxisome proliferator-activated receptor-gamma 2 expression in type I domestic mice. Endocrinology. 2005;146:3622-31. (Pubitemid 41058134)
36. Botolin S, McCabe LR. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology. 2007;148:198-205. (Pubitemid 46021451)
37. Martin L, McCabe LR. Type I diabetic bone phenotype is location but not gender dependent. Histochem Cell Biol. 2007;128:125-33. (Pubitemid 47197932)
38. Duque G. As a matter of fat: new perspectives on the understanding of age-related bone loss. BoneKEy-Osteovision. 2007;4:129-40.
39. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor gamma2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 2002;143:2376-84. (Pubitemid 34521584)
40. Gimble JM. The function of adipocytes in the bone marrow stroma. New Biol. 1990;2:304-12. (Pubitemid 20358991)
41. Tavassoli M. Marrow adipose cells and hemopoiesis: an interpretive review. Exp Hematol. 1984;12:139-46.
42. Gimble JM, Robinson CE, Wu X, Kelly KA. The function of adipocytes in the bone marrow stroma: an update. Bone. 1996;19:421-8.
43. Payne MWC, Uhthoff HK, Trudel G. Anemia of immobility: caused by adipocyte accumulation in bone marrow. Med Hypotheses. 2007;69:778-86. (Pubitemid 47248136)
44. Nuttall ME, Gimble JM. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol. 2004;4:290-4. (Pubitemid 38585315)
45. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME. Playing with bone and fat. J Cell Biochem. 2006;98:251-66.
46. Corre J, Planat-Benard V, Corberand JX, Pénicaud L, Casteilla L, Laharrague P. Human bone marrow adipocytes support complete myeloid and lymphoid differentiation from human CD34 cells. Br J Haematol. 2004;127:344-7. (Pubitemid 39468950)
47. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ 2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell. 2004;3:379-89. (Pubitemid 40246708)
48. Di Iorgi N, Mittelman SD, Gilsanz V. Differential effect of marrow adiposity and visceral and subcutaneous fat on cardiovascular risk in young, healthy adults. Int J Obes (Lond). 2008;32:1854-60.
49. Rozman C, Feliu E, Berga L, Reverter JC, Climent C, Ferrán MJ. Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: a stereological study. Exp Hematol. 1989;17:34-7. (Pubitemid 19036773)
50. Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop. 1971;80:147-54.
51. Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology. 2001;2:165-71. (Pubitemid 32851325)
52. Burkhardt R, Kettner G, Bohm W, Schmidmeier M, Schlag R, Frisch B, et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone. 1987;8:157-64. (Pubitemid 17111858)
53. Minaire P, Edouard C, Arlot M, Meunier PJ. Marrow changes in paraplegic patients. Calcif Tissue Int. 1984;36:338-40. (Pubitemid 14072404)
54. Belin de Chantemele E, Blanc S, Pellet N, Duvareille M, Ferretti G, Gauquelin-Koch G, et al. Does resistance exercise prevent body fluid changes after a 90-day bed rest? Eur J Appl Physiol. 2004;92:555-64. (Pubitemid 39248370)
55. LeBlanc A, Schneider V, Shackelford L, West S, Oganov V, Bakulin A, et al. Bone mineral and lean tissue loss after long duration space flight. J Musculoskel Neuron Interact. 2000;1:157-60.
56. Wronski TJ, Walsh CC, Ignaszewski LA. Histologic evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone. 1986;7:119-23. (Pubitemid 16081134)
57. Forsen L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia. 1999;42:920-5. (Pubitemid 29369598)
58. Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751-64. (Pubitemid 40585297)
59. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med. 2001;226:507-20. (Pubitemid 32524497)
60. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 2006;20:161-71.
61. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006;2:35-43. (Pubitemid 43153647)
62. Rodríguez JP, Garat S, Gajardo H, Pino AM, Seitz G. Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics. J Cell Biochem. 1999; 75:414-23. (Pubitemid 29521650)
63. Rodríguez JP, Montecinos L, Ríos S, Reyes P, Martínez J. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J Cell Biochem. 2000;79:557-65.
64. Astudillo P, Ríos S, Pastenes L, Pino AM, Rodríguez JP. Increased adipogenesis of osteoporotic human-mesenchymal stem cells (MSCs) characterizes by impaired leptin action. J Cell Biochem. 2008;103:1054-65. (Pubitemid 351342599)
65. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003;14:137-45. (Pubitemid 36733912)
66. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab. 2003;14:398-403. (Pubitemid 37392211)
67. Arner P. Free fatty acids-do they play a central role in type 2 diabetes? Diabetes Obes Metab. 2001;3:11-9.
68. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-81. (Pubitemid 30666380)
69. Abella E, Feliu E, Granada I, Millá F, Oriol A, Ribera JM, et al. Bone marrow changes in anorexia nervosa are correlated with the amount of weight loss and not with other clinical findings. Am J Clin Pathol. 2002;118:582-8. (Pubitemid 44698515)
70. Wehrli FW, Hopkins JA, Hwang SN, Song HK, Snyder PJ, Haddad JG. Cross-sectional study of osteopenia with quantitative MR imaging and bone densitometry. Radiology. 2000;217:527-38.
71. Yeung DK, Griffith JF, Antonio GE, Lee FK, Woo J, Leung PC. Osteoporosis is associated with increased marrow fat content and decreased marrow fat unsaturation: a proton MR spectroscopy study. J Magn Reson Imaging. 2005;22:279-85. (Pubitemid 41045443)
72. Griffith JF, Yeung DK, Antonio GE, Lee FK, Hong AW, Wong SY, et al. Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology. 2005;236:945-51. (Pubitemid 41170858)
73. Griffith JF, Yeung DK, Tsang PH, Choi KC, Kwok TC, Ahuja AT, et al. Compromised bone marrow perfusion in osteoporosis. J Bone Miner Res. 2008;23:1068-75. (Pubitemid 351915729)
74. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteopenic disorders. J Bone Min Res. 1998;13:371-82. (Pubitemid 28146219)
75. Bianco P, Robey PG. Diseases of bone and stromal cell lineage. J Bone Min Res. 1999;14:336-41. (Pubitemid 29106710)
76. Rodríguez JP, Ri?os S, Fernández M, Santibañez JF. Differential activation of ERK1,2 MAP kinase signaling pathway in mesenchymal stem cell from control and osteoporotic postmenopausal women. J Cell Biochem. 2004;92:745-54. (Pubitemid 44264265)
77. Prusty D, Park B-H, Davis KE, Farmer SR. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferators-activated receptor g (PPARg) and C/EBPa gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem. 2002;277:46226-32. (Pubitemid 35417614)
78. Takahashi Y, Okimura Y, Mizuno I, Iida K, Takahashi T, Kaji H, et al. Leptin induce mitogen-activated protein kinase-dependent proliferation of C3H10T1/2 cells. J Biol Chem. 1997;272:12897-900. (Pubitemid 27216702)
79. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140:1630-8. (Pubitemid 29149231)
80. Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Min Res. 2001;16:1426-33. (Pubitemid 32675194)
81. Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, De Simone L, Orlandi R, et al. Body weight, body fat distribution, and hormonal replacement therapy in early post menopausal women. J Clin Endocrinol Metab. 1997;82:414-7. (Pubitemid 27068603)
82. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056-61. (Pubitemid 24317698)
83. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;86:3689-98.
84. Heim M, Frank O, Kampmann G, Sochocky N, Pennimpede T, Fuchs P, et al. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. Endocrinology. 2004;145:848-59. (Pubitemid 38183829)
85. Pino AM, Rodríguez JM, Ríos S, Astudillo P, Leiva L, Seitz G, et al. Aromatase activity of human mesenchymal stem cells is stimulated by early differentiation, vitamin D and leptin. J Endocrinol. 2006;191:717-27.
86. Schweikert HU, Wolf L, Romalo G. Oestrogen formation from androstenedione in human bone. Clin Endocrinol (Oxf). 1995;43:37-42.
87. Janssen JMMF, Bland R, Hewison M, Coughtrie MW, Sharp S, Arts J, et al. Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function. J Cell Biochem. 1999;75:528-37. (Pubitemid 29521659)
88. Compston J. Editorial: local biosynthesis of sex steroids in bone. J Clin Endocrinol Metab. 2002;87:5398-400. (Pubitemid 36034332)
89. Issa S, Schnabel D, Feix M, Wolf L, Schaefer HE, Russell DW, et al. Human osteoblas-like cells express predominantly steroid 5a-reductase type 1. J Clin Endocrinol Metab. 2002;87:5401-7. (Pubitemid 36034333)
90. Tanaka S, Haji M, Nishi Y, Yanase T, Takayanagi R, Nawata H. Aromatase activity in human osteoblast-like osteosarcoma cell. Calcif Tissue Int. 1993;52:107-9. (Pubitemid 23087939)
91. Sasano H, Uzuki M, Sawai T, Nagura H, Matsunaga G, Kashimoto O, et al. Aromatase in human bone tissue. J Bone Min Res. 1997;12:1416-23. (Pubitemid 27375384)
92. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor - α knockout mice. Proc Natl Acad Sci USA. 2000;97:12729-34.
93. Jones ME, Thorburn AW, Britt KN, Hewitt KN, Wreford NG, Proietto J, et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci USA. 2000;97:12735-40.
94. Okazaki R, Inoue D, Shibata M, Saika M, Kido S, Ooka H, et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER)α or β. Endocrinology. 2002;143:2349-56. (Pubitemid 34521581)
95. Riggs BI, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279-302. (Pubitemid 34651948)
96. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab. 2004;89:5898-907. (Pubitemid 39628389)